|Print Page Close Window|
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two ot...Read More
NASDAQ PTLA (Common Stock)
$34.83 - 1.28
03/16/18 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.